03.21.18
Synexus, a site network for clinical trials, has opened its first dedicated research center in the Czech Republic. Synexus has been operating in the country for two years through affiliated sites and this investment in a new clinic expands its clinical research activities in the region.
The new clinic has its own dedicated team of GCP (good clinical practices) trained doctors and nurses. With the opening of the Prague facility, Synexus is now working with almost 200 clinical research sites across the globe.
“The opening of our new Prague clinic is an exciting and much-anticipated development for Synexus and our clients,” said Dr. Radosław Janiak, the company’s president and chief operating officer. “Not only does this significantly expand our capabilities in Eastern Europe, but our high-tech laboratory and patient facilities also mean our clinic can welcome greater numbers of patients and run more complex trials.
The center was unveiled to senior executives of pharmaceutical companies and CROs from across Central and Eastern Europe by Dr. Janiak, who was accompanied by Wojciech Szczepanik, Synexus’ managing director for Central and Eastern Europe.
The new clinic has its own dedicated team of GCP (good clinical practices) trained doctors and nurses. With the opening of the Prague facility, Synexus is now working with almost 200 clinical research sites across the globe.
“The opening of our new Prague clinic is an exciting and much-anticipated development for Synexus and our clients,” said Dr. Radosław Janiak, the company’s president and chief operating officer. “Not only does this significantly expand our capabilities in Eastern Europe, but our high-tech laboratory and patient facilities also mean our clinic can welcome greater numbers of patients and run more complex trials.
The center was unveiled to senior executives of pharmaceutical companies and CROs from across Central and Eastern Europe by Dr. Janiak, who was accompanied by Wojciech Szczepanik, Synexus’ managing director for Central and Eastern Europe.